COMT inhibition in the treatment of Parkinson’s disease

@article{Ruottinen1998COMTII,
  title={COMT inhibition in the treatment of Parkinson’s disease},
  author={H. Ruottinen and U. Rinne},
  journal={Journal of Neurology},
  year={1998},
  volume={245},
  pages={P25-P34}
}
Abstract A new approach in the treatment of Parkinson’s disease is the inhibition of catechol-O-methyltransferase (COMT) with new generation COMT inhibitors, entacapone and tolcapone. Entacapone acts mainly peripherally whereas tolcapone acts both peripherally and centrally. They induce a dose-dependent inhibition of COMT activity in erythrocytes and a significant decrease in the plasma levels of 3-O-methyldopa, indicating their effectiveness as COMT inhibitors. Consequently, they increase the… Expand
Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease
TLDR
It is now recommended that tolcapone be administered only in patients with motor fluctuations who are no longer satisfactorily treated with other medications for Parkinson’s disease, and routine liver monitoring is now mandatory with this agent. Expand
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
  • J. Najib
  • Medicine
  • Clinical therapeutics
  • 2001
TLDR
In clinical trials, adjuvant treatment with entacapone appeared to be an effective and well-tolerated therapeutic strategy in patients with Parkinson's disease who experience fluctuations in the response to levodopa therapy. Expand
Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson’s Disease
TLDR
It is suggested that this interaction study, performed in patients and using clinical data, excludes any central effects of tolcapone or any inhibiting effect of 3-OMD on levodopa permeation through the blood-brain barrier, which otherwise would have led to a decrease in the EC50 oflevodopa. Expand
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
TLDR
The STRIDEPD study failed to prove the benefit of continuous dopaminergic stimulation with triple therapy in a clinical setting, and clear evidence has been presented indicating homocysteine as a risk factor for vascular diseases, cognitive impairment, and dementia. Expand
Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
  • T. Müller
  • Medicine
  • Patient preference and adherence
  • 2009
TLDR
Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of motor complications to a certain extent, and there is still a need to confirm this in a clinical trial, which is under way. Expand
Interventions to Achieve Tonic Exposure to Levodopa: Delaying or Preventing the Onset of Motor Complications
TLDR
In patients with stable responses to long‐term levodopa, addition of tolcapone significantly reduced the onset of motor fluctuations, and data suggest that COMT inhibition may enhancelevodopa's short‐ and long-term efficacy. Expand
Adenosine A2A receptor antagonist treatment of Parkinson’s disease
Background: Observations in animal models suggest that A2A antagonists confer benefit by modulating dopaminergic effects on the striatal dysfunction associated with motor disability. ThisExpand
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease
TLDR
Comparisons of the effects of a 3-month therapy with catechol-O-methyltransferase (COMT) inhibitors and entacapone on L-DOPA metabolism in parkinsonian patients with motor fluctuations confirm the different profiles of activity of the two drugs. Expand
Catechol-O-Methyltransferase Decreases Levodopa Toxicity In Vitro
TLDR
It was found that 3-O-methyldopa, unlike levodopa, was not toxic to all cells examined, and addition of purified COMT to levodOPA prevented its auto-oxidation and markedly attenuated its cytotoxicity in vitro. Expand
Tolcapone-Related Liver Dysfunction
Levodopa is the cornerstone of idiopathic Parkinson’s disease (PD) treatment. However, after long-term use of levodopa, a significant percentage of patients experience motor fluctuations, whichExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
TLDR
Entacapone (OR-611), a novel COMT inhibitor, was assessed in 12 patients with Parkinson's disease and motor fluctuations in a randomised, double-blind, cross-over, single dose study. Expand
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
TLDR
It is concluded that entacapone may be a helpful adjunct to levodopa in the treatment of PD and well tolerated, judged by the lack of significant changes in hemodynamic and safety variables. Expand
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
TLDR
Dose-related responses to entacapone demonstrated its value in the treatment of parkinsonian patients withlevodopa-related fluctuations by prolonging the antiparkinsonian response to the levodopa dose. Expand
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
TLDR
Peripheral COMT inhibition with entacapone increased significantly the bioavailability of levodopa and prolonged its antiparkinsonian effect after a single dose and after repeated dosing for 4 weeks, and seems to be a valuable adjuvant tolevodopa treatment in parkinsonian patients with end-of-dose failure. Expand
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
TLDR
Tolcapone appears to be well tolerated and could be helpful as an adjuvant treatment to levodopa in parkinsonian patients with motor fluctuations. Expand
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
TLDR
Plasma concentrations of tolcapone correlated with inhibition of COMT activity in erythrocytes and suppression of 3-OMD levels, but not with changes in levodopa pharmacokinetics. Expand
Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
TLDR
It is concluded that inhibition of COMT by entacapone increases the plasma half-life of levodopa and augments the antiparkinsonian effects of single and repeated doses of Levodopa. Expand
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
TLDR
Tolcapone may be a useful adjunct to L-DOPA/carbidopa and decreased the accumulation of homovanillic acid and increased the area under the curve of the plasma L-dOPA concentration versus time curve and decreasedThe effects of acute catechol-O-methyltransferase (COMT) inhibition on L- DOPA pharmacokinetics were studied. Expand
Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
TLDR
Multiple daily dosing with tolcapone would be expected to safely reduce the wearing-off phenomenon associated with levodopdcarbidopa therapy, which frequently complicates levodopa therapy of Parkinson's disease. Expand
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
TLDR
Entacapone improves the pharmacokinetic profile oflevodopa when used in combination with a CR levodopa preparation, as it does with a standard levodOPA preparation. Expand
...
1
2
3
4
5
...